Healthcare services provider AdaptHealth Corp. (NASDAQ: AHCO) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 5.4% year on year to $819.8 million. The company expects the full year’s revenue to be around $3.49 billion, close to analysts’ estimates. Its non-GAAP loss of $0.05 per share was significantly below analysts’ consensus estimates.

Is now the time to buy AHCO? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

AdaptHealth’s first quarter was driven by the rapid onboarding of a large capitated contract, which involved transitioning hundreds of thousands of patients to its platform. Management noted this was the largest such operational undertaking in home medical equipment history. However, the quarter was also marked by elevated labor costs associated with the accelerated transition, leading to a miss on profit metrics. CEO Suzanne Foster described the performance as a “monumental quarter,” but acknowledged the operational complexity and added costs, stating, “the extra implementation spend was the right decision for the relationship and the patients.”

Looking ahead, AdaptHealth’s guidance is shaped by expectations for continued growth in capitated agreements, further operational improvements, and technology-driven efficiency gains. Management believes that as recent investments in AI and patient-facing digital platforms scale, they will contribute to improved margins in the back half of the year and into 2027. CFO Jason Clemens emphasized that, while cost containment remains a priority, the company is optimistic about expanding its footprint through additional partnerships, stating, “our discussions regarding new capitated deals remain active and promising, and we are optimistic about announcing additional partnerships soon.”

Key Insights from Management’s Remarks

Management attributed the quarter’s revenue outperformance to accelerated onboarding of a major capitated contract, with organic growth supported by all core segments. Margin pressure stemmed from higher labor expenses tied to this transition, while investments in digital platforms began to yield operational improvements.

• Capitated contract acceleration: The successful and rapid onboarding of over 10 million new members under a large capitated agreement required the establishment of 35 new locations, resulting in significant one-time labor costs and operational complexity.
• Organic growth in core segments: All four business segments—Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home—delivered positive organic growth, with Sleep Health performing particularly well due to increased demand for therapies addressing sleep apnea. However, Wellness at Home's reported revenue declined 10.3% year over year; after adjusting for disposed non-core assets, Wellness at Home delivered 11% organic growth.
• Labor cost headwinds: Elevated labor expenses, totaling $12 million above normal, were necessary to ensure a smooth patient transition for the new contract. Management expects these costs to normalize by the end of the second quarter as the onboarding process is completed.
• Technology and AI initiatives: Investments in AI-enabled scheduling and patient portals have started to improve scheduling efficiency and patient experience, with 25% of scheduling now automated. Management anticipates that financial benefits from these initiatives will be more pronounced in 2027.
• Portfolio focus and asset pruning: AdaptHealth continued to divest non-core assets, especially within the Wellness at Home segment, to concentrate resources on its core growth areas of Sleep and Respiratory Health. This strategic focus is expected to support future organic growth and margin improvement.

Drivers of Future Performance

Management’s outlook is anchored by the ramp-up of capitated contracts, ongoing cost discipline, and the scaling of digital and AI-driven efficiencies across the business.

• Capitated contract margin ramp: As the new capitated agreement transitions into steady-state operation, management expects improved margins due to lower labor costs and higher revenue visibility. CFO Jason Clemens indicated that a full quarter of revenue from this contract will contribute to an EBITDA margin improvement, with further gains as cost containment efforts take effect.
• Technology-driven operational gains: The rollout of AI-powered scheduling and patient engagement tools is designed to streamline workflows and enhance the patient experience. While financial benefits were limited in Q1, management projects that these improvements will begin to positively impact margins in the back half of the year and even more so in 2027.
• Pipeline for additional contracts: AdaptHealth’s management remains optimistic about securing additional capitated agreements, which would further expand its member base and geographic reach. The company expects future deals to require less upfront investment, given its expanded footprint and infrastructure, potentially accelerating profitability.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be watching (1) the normalization of labor costs and realization of margin improvement as the new capitated contract matures, (2) the pace at which AI and digital initiatives drive operational efficiency and patient engagement, and (3) the announcement and successful onboarding of additional capitated agreements. Execution in the Diabetes Health segment and ongoing asset portfolio optimization will also remain key areas of focus.

AdaptHealth currently trades at $11.87, down from $13.06 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.